MX2023013165A - Molecula de union a antigeno que se une especificamente a rankl y ngf, y su uso medico. - Google Patents

Molecula de union a antigeno que se une especificamente a rankl y ngf, y su uso medico.

Info

Publication number
MX2023013165A
MX2023013165A MX2023013165A MX2023013165A MX2023013165A MX 2023013165 A MX2023013165 A MX 2023013165A MX 2023013165 A MX2023013165 A MX 2023013165A MX 2023013165 A MX2023013165 A MX 2023013165A MX 2023013165 A MX2023013165 A MX 2023013165A
Authority
MX
Mexico
Prior art keywords
rankl
ngf
medical use
molecule specifically
antigen binding
Prior art date
Application number
MX2023013165A
Other languages
English (en)
Inventor
Hua Ying
Weikang Tao
Xiaoling Gu
Langyong Mao
Original Assignee
Jiangsu Hengrui Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Pharmaceuticals Co Ltd filed Critical Jiangsu Hengrui Pharmaceuticals Co Ltd
Publication of MX2023013165A publication Critical patent/MX2023013165A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una molécula de unión a antígeno que se une específicamente a RANKL y NGF, y a un uso médico de la misma. Específicamente, se proporcionan un nuevo anticuerpo anti-RANKL, un anticuerpo biespecífico dirigido a RANKL y NGF, un método de preparación para el anticuerpo y un uso del mismo en el tratamiento o prevención de enfermedades.
MX2023013165A 2021-05-12 2022-05-12 Molecula de union a antigeno que se une especificamente a rankl y ngf, y su uso medico. MX2023013165A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110515444 2021-05-12
PCT/CN2022/092333 WO2022237856A1 (zh) 2021-05-12 2022-05-12 特异性结合rankl和ngf的抗原结合分子及其医药用途

Publications (1)

Publication Number Publication Date
MX2023013165A true MX2023013165A (es) 2023-11-30

Family

ID=84028176

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013165A MX2023013165A (es) 2021-05-12 2022-05-12 Molecula de union a antigeno que se une especificamente a rankl y ngf, y su uso medico.

Country Status (10)

Country Link
EP (1) EP4339207A1 (es)
JP (1) JP2024518081A (es)
KR (1) KR20240006586A (es)
CN (1) CN117062837A (es)
AU (1) AU2022272427A1 (es)
BR (1) BR112023022707A2 (es)
CA (1) CA3218542A1 (es)
MX (1) MX2023013165A (es)
TW (1) TW202306990A (es)
WO (1) WO2022237856A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024104409A1 (zh) * 2022-11-16 2024-05-23 苏州盛迪亚生物医药有限公司 一种含抗rankl-ngf双特异性抗体的药物组合物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2288600C (en) 1997-05-02 2010-06-01 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
SI2263692T1 (sl) 2002-12-24 2020-10-30 Rinat Neuroscience Corp. Anti-NGF protitelesa in postopki, v katerih se le-ta uporabljajo
ES2592271T3 (es) 2005-03-31 2016-11-29 Chugai Seiyaku Kabushiki Kaisha Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos
AR060070A1 (es) 2006-03-24 2008-05-21 Merck Patent Gmbh Dominios proteicos heterodimericos obtenidos por ingenieria
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
KR20120125601A (ko) 2007-05-24 2012-11-16 아블린쓰 엔.브이. Ｒａｎｋ-ｌ에 대한 아미노산 서열, 및 이를 포함하는 골 질환 및 장애 치료용 폴리펩티드
EP2235064B1 (en) 2008-01-07 2015-11-25 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
AU2010343057B2 (en) 2009-12-29 2017-02-23 Aptevo Research And Development Llc Heterodimer binding proteins and uses thereof
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
BR112013011811A2 (pt) 2010-11-05 2023-02-23 Zymeworks Inc Modelo de anticorpo heterodimérico estável com mutações no domínio fc
GB201114858D0 (en) 2011-08-29 2011-10-12 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of using the same
JP6258194B2 (ja) 2011-05-06 2018-01-10 ネックスヴェット オーストラリア プロプライエタリー リミテッド 抗神経成長因子抗体並びに前記の製造及び使用方法
MY160884A (en) 2011-05-06 2017-03-31 Nexvet Australia Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
RU2661677C2 (ru) 2011-05-27 2018-07-18 Аблинкс Нв Ингибирование резорбции кости с помощью связывающих rank-l пептидов
LT2794905T (lt) 2011-12-20 2020-07-10 Medimmune, Llc Modifikuoti polipeptidai, skirti bispecifinių antikūnų karkasams
KR102382304B1 (ko) 2012-04-20 2022-04-04 메뤼스 엔.페. Ig-유사 분자의 제조방법 및 제조수단
CN102827277B (zh) * 2012-04-26 2014-12-10 拜明(苏州)生物技术有限公司 抗人血清白蛋白单链抗体及其碳端连接多肽药物的方法
WO2013176469A1 (ko) 2012-05-21 2013-11-28 이화여자대학교 산학협력단 파골세포분화를 억제할 수 있는 항체
US10227411B2 (en) * 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
JOP20190255A1 (ar) * 2017-04-28 2019-10-27 Amgen Inc صيغ أجسام مضادة لـ rankl بشري، وطرق لاستخدامها
CA3132656A1 (en) * 2019-04-30 2020-11-05 Instituto De Medicina Molecular Joao Lobo Antunes Rank pathway inhibitors in combination with cdk inhibitors

Also Published As

Publication number Publication date
AU2022272427A1 (en) 2023-12-14
BR112023022707A2 (pt) 2024-01-16
JP2024518081A (ja) 2024-04-24
TW202306990A (zh) 2023-02-16
KR20240006586A (ko) 2024-01-15
CN117062837A (zh) 2023-11-14
CA3218542A1 (en) 2022-11-17
WO2022237856A1 (zh) 2022-11-17
EP4339207A1 (en) 2024-03-20

Similar Documents

Publication Publication Date Title
MX2020008075A (es) Anticuerpos anti-ctla4 y métodos para elaborarlos y usarlos.
PH12019500545A1 (en) Cd3 binding antibodies
MX2018010331A (es) Agentes de ligacion al factor de crecimiento endotelial vascular/ligando 4 similar a delta (vegf/dll4) y usos de los mismos.
PH12019502484A1 (en) Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
MX2018016404A (es) Anticuerpos de union a cd3.
MX2022009936A (es) Anticuerpos que se unen al dominio v-set que contiene el inhibidor de activacion de celulas t 1 (b7h4).
EA201490957A1 (ru) Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела
MX2021015888A (es) Fusión de un anticuerpo que se une a cea y 4-1bbl.
NZ601580A (en) Therapeutic methods using anti-cd200 antibodies
PH12020551447A1 (en) Antibodies
MX2014000555A (es) Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.
MX2020010913A (es) Anticuerpos anti-cd27 y anti-pd-l1 y constructos biespecíficos.
WO2021227307A8 (zh) 抗cd73抗体及其用途
WO2019234241A8 (en) ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT
MX2021014193A (es) Moleculas de enlace biespecificas anti-ror1/anti-cd3.
MX2020008718A (es) Anticuerpos de union a bcma y usos de los mismos.
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
MX2022008471A (es) Anticuerpo anti-angptl3 y uso del mismo.
MX2023013165A (es) Molecula de union a antigeno que se une especificamente a rankl y ngf, y su uso medico.
MX2023002194A (es) Moleculas multiespecificas de union a antigenos dirigidas al vih y metodos de uso.
MX2020002750A (es) Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
MX2023007178A (es) Complejo de anticuerpo anti-il-4r o fragmento de enlace a antigeno y uso medico del mismo.
MX2021008453A (es) Formulaciones de anticuerpos que se unen a cd137 humano y usos de los mismos.
MX2022003762A (es) Molécula de unión específica para el factor inhibidor de la leucemia (lif) y uso de la misma.
MX2023003749A (es) Anticuerpos capaces de unirse al receptor huerfano 2 similar a tirosina-cinasa receptora (ror2) y anticuerpos biespecificos que se unen a ror2 y al cumulo de diferenciacion 3 (cd3).